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AbsTrACT
Objectives Pre-exposure prophylaxis (PreP) is a highly 
effective method of HiV prevention for men who have 
sex with men (MSM). However, uncertainty remains 
around the optimal eligibility criteria for PreP, specifically 
whether there are subgroups at low risk of HiV for whom 
PreP might not be warranted.
Methods PrOUD was an open-label waitlist trial 
design that randomised MSM attending participating 
sexual health centres in england to receive PreP 
immediately (iMM) or after a deferral period of 1 year 
(DeF). this analysis is based on participants who were 
randomised to the deferred arm, when they did not have 
access to PreP. HiV incidence was compared between 
subgroups defined by baseline characteristics.
results Overall, 21 participants acquired HiV infection 
over 239.3 person-years (PY) follow-up, yielding an 
incidence rate of 8.8/100 PY (95% ci 5.4 to 13.4). two 
highly significant predictors for HiV acquisition were 
identified. Men with a self-reported diagnosis of syphilis, 
rectal chlamydia (ct) or rectal gonorrhoea (gc) in the 
previous 12 months had an incidence of 17.2/100 PY 
(95% ci 9.7 to 28.5); those reporting receptive anal 
intercourse without a condom (ncrai) with two or more 
partners in the previous 3 months had an incidence of 
13.6/100 PY (95% ci 7.9 to 21.7). the incidence rate 
among participants lacking both of these risk factors was 
1.1/100 PY (1/87.6, 95% ci 0.03 to 6.4).
Conclusions the high HiV incidence in PrOUD 
suggests that most participants appropriately judged 
their need for PreP. eligibility criteria for a PreP 
programme can therefore be broad, as in the current 
guidelines. However, a recent history of syphilis or rectal 
ct/gc, or multiple ncrai partners indicates a high 
imminent risk of HiV infection. MSM with any of these 
characteristics should be offered PreP as a matter of 
urgency.
InTrOduCTIOn
Oral pre-exposure prophylaxis (PrEP) has been 
shown to be a highly effective method of HIV 
prevention for men who have sex with men 
(MSM).1–3 At a population level, this effect is medi-
ated both through the direct avoidance of infections 
among individuals who take PrEP and the indirect 
prevention of infections that would have occurred 
subsequently in the transmission chain.4 In the UK, 
new HIV diagnoses among MSM remained stable 
for over a decade but have declined in the last 2 
years, likely mainly as a result of the combination of 
PrEP, an increase in HIV testing and routine rapid 
treatment after diagnosis.5 6
An important issue in PrEP roll-out programmes 
is participant eligibility since cost-effectiveness is 
critically dependent on the HIV incidence in the 
target population. From a clinical perspective the 
risk:benefit ratio of PrEP may be disadvantageous 
in individuals at negligible risk of HIV infection, for 
example, those in a monogamous serodifferent rela-
tionship whose partner is virologically suppressed 
on treatment. WHO guidelines recommend PrEP in 
populations with an annual incidence greater than 
3%.7 However, individual risk of acquiring HIV 
infection is highly heterogeneous and implementa-
tion of this recommendation is not straightforward. 
Several organisations have issued PrEP guidelines, 
which include eligibility criteria for MSM.8–10 The 
central criterion in all guidelines is reported anal 
intercourse without a condom, although with no 
explicit reference to the number of partners. Other 
criteria include the use of postexposure prophylaxis 
(PEP), a recent diagnosis with a bacterial STI and a 
history of sexualised drug use.
PROUD was an open-label trial that randomised 
MSM attending participating sexual health centres 
in the England to receive PrEP immediately or after 
a deferral period of 1 year (waitlist design).2 11 A 
key finding from the trial was the unexpectedly 
high HIV incidence during the deferral period (9 
per 100 person-years [PY]). Here we present an 
analysis of baseline risk factors for the acquisition 
of HIV among men randomised to the deferred 
group before they had access to PrEP. The objective 
of this analysis was to examine the relative impor-
tance of the recommended eligibility criteria for 
a future PrEP programme, identify any other risk 
factors and explore whether there are subgroups 
at low risk of HIV for whom PrEP might not be 
warranted. The results should inform eligibility 
criteria for MSM in the UK and similar populations 
elsewhere in Europe.
MeThOds
Participants were enrolled into the PROUD trial 
between November 2012 and April 2014, and 
were randomly assigned to start PrEP immedi-
ately at enrolment (IMM) or after a 1-year deferral 
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Table 1 HIV incidence by baseline characteristics
Characteristic Participants, n (%) Total PY hIV infections
Incidence rate 
(per 100 PY) 95% CI rate ratio 95% CI P value*
Total 268 (100.0) 239.3 21 8.8 5.4 to 13.4 – – –
Age (years) 18–24 27 (10.1) 24.6 3 12.2 2.5 to 35.7 1.4 0.3 to 4.8 0.26
25–34 104 (38.8) 94.5 9 9.5 4.4 to 18.1 1.1 0.4 to 2.8
35–49 116 (43.3) 101.0 9 8.9 4.1 to 16.9 1.0 –
50+ 21 (7.8) 19.1 0 0 0 to 19.3† 0.4 0 to 2.1†
University degree No 101 (38.0) 90.6 6 6.6 2.4 to 14.4 1.0 – 0.38
Yes 165 (62.0) 146.7 15 10.2 5.7 to 16.9 1.5 0.6 to 4.3
Full-time employment No 68 (25.8) 63.1 3 4.8 1.0 to 13.9 1.0 – 0.20
Yes 196 (74.2) 173.0 18 10.4 6.2 to 16.4 2.2 0.7 to 9.3
Born in UK No 107 (40.2) 96.6 9 9.3 4.3 to 17.7 1.0 – 0.84
Yes 159 (59.8) 140.7 12 8.5 4.4 to 14.9 0.9 0.4 to 2.3
Ethnicity White 218 (82.6) 192.3 19 9.9 5.9 to 15.4 1.0 – 0.32
Black, Asian and 
minority
46 (17.4) 42.8 2 4.7 0.6 to 16.9 0.5 0.07 to 1.8
London site No 81 (30.2) 71.8 6 8.4 3.1 to 18.2 1.0 – 0.91
Yes 187 (69.8) 167.4 15 9.0 5.0 to 14.8 1.1 0.4 to 3.0
Circumcised No 185 (70.1) 166.2 17 10.2 6.0 to 16.4 1.0 – 0.30
Yes 79 (29.9) 69.8 4 5.7 1.6 to 14.7 0.6 0.2 to 1.6
Relationship status Living with partner 73 (27.5) 66.9 6 9.0 3.3 to 19.5 0.9 0.3 to 2.3 0.32
Not living with 
partner
46 (17.4) 42.1 2 4.7 0.6 to 17.2 0.5 0.07 to 1.8
Single 146 (55.1) 127.3 13 10.2 5.4 to 17.5 1.0 –
High depression 
score‡
No 233 (92.1) 205.1 19 9.3 5.6 to 14.5 1.0 – 0.68
Yes 20 (7.9) 18.5 1 5.4 0.1 to 30.2 0.6 0.03 to 3.2
Number of HIV tests§ 0–2 91 (35.5) 82.4 5 6.1 2.0 to 14.2 0.7 0.2 to 2.1 0.13
3–4 122 (47.7) 106.1 9 8.5 3.9 to 16.1 1.0 –
5+ 43 (16.8) 38.1 6 15.7 5.8 to 34.2 1.9 0.6 to 5.3
Key STI§ No 155 (60.5) 140.4 5 3.6 1.2 to 8.3 1.0 – 0.001
Rectal CT/GC or 
syphilis
101 (39.5) 87.0 15 17.2 9.7 to 28.5 4.8 1.8 to 14.9
PEP use§ No 159 (63.3) 142.3 11 7.7 3.9 to 13.8 1.0 – 0.41
Yes 92 (36.7) 80.3 9 11.2 5.1 to 21.3 1.4 0.6 to 3.6
Number of ncRAI 
partners¶
0 32 (12.5) 29.8 1 3.4 0.08 to 18.7 1.2 0.04 to 16.0 0.01
1 78 (30.5) 72.5 2 2.8 0.3 to 10.0 1.0 –
2–4 81 (31.6) 68.7 8 11.6 5.0 to 22.9 4.2 1.0 to 29.1
5–9 35 (13.7) 30.9 5 16.2 5.3 to 37.8 5.9 1.2 to 43.7
10+ 30 (11.7) 25.7 4 15.6 4.2 to 39.9 5.7 1.0 to 44.1
Drug use associated 
with chemsex¶**
No 135 (52.3) 121.9 7 5.7 2.3 to 11.8 1.0 – 0.17
Yes 123 (47.7) 108.1 12 11.1 5.7 to 19.4 1.9 0.8 to 5.2
Poppers¶ No 129 (50.0) 117.9 10 8.5 4.1 to 15.6 1.0 – 0.91
Yes 129 (50.0) 112.1 9 8.0 3.7 to 15.2 0.9 0.4 to 2.4
Missing data (total, events lost due to missing exposure data) for education (2, 0); employment status (4, 0); born in UK (2, 0); ethnicity (4, 0); circumcised (4, 0); relationship (3, 0); depression (15, 
1); number of HIV tests (12, 1); key STI (12, 1); PEP (17, 1); ncRAI (12, 1); chemsex (10, 2); poppers (10, 2).
Quantitative variables were grouped according to clinical considerations.
Key STIs (rectal chlamydia [CT], rectal gonorrhoea [GC] or syphilis).
*P value for trend calculated for ordered categorical variables: ncRAI partners, anal intercourse (AI) partners, age and HIV tests. P value for relationship status compares single versus not living 
with partner. P value for ethnicity compares white against all other categories combined.
†One sided, 97.5% CI.
‡Defined by the Patient Health Questionnaire-9 (PHQ-9) score, high score ≥10.
§Occurred in 12 months prior to baseline visit.
¶Occurred in the 90 days prior to baseline visit.
**Chemsex-associated drugs defined as the use of methamphetamine, gamma hydroxybutyrate (GHB), mephedrone or ketamine.
PEP, postexposure prophylaxis; PY, person-years; ncRAI, receptive anal intercourse without a condom.
period (DEF). Eligible participants were HIV negative; tested 
by a routinely used assay in the previous 4 weeks or on the 
day of enrolment, male at birth, aged 18 years or older, had 
attended the enrolling clinic previously, and reported anal sex 
without a condom in the previous 90 days and stated it likely 
that this behaviour would recur again in the next 90 days. At 
enrolment, participants’ self-completed a questionnaire on: 
demographic characteristics, including age, education, country 
of birth, whether they had been circumcised and relationship 
status; self-reported history of number of HIV/STI screens, STIs 
and the use of post-exposure prophylaxis (PEP) in the previous 
12 months; and sexual behaviour in the previous 90 days. 
Sexual behaviour included the use of poppers and drugs most 
commonly associated with chemsex (defined in the footnote to 
table 1), and the number of different anal sex partners (total, 
receptive sex, insertive sex, receptive/insertive sex without a 
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Table 2 Associations between STIs and HIV incidence rate
Participants, n (%) Total PY hIV infections (n)
Incidence rate (per 
100 PY) 95% CI
Rectal CT/GC or syphilis (key STI) 101 (39.4) 87.0 15 17.2 9.7 to 28.5
Syphilis 30 (11.7) 24.0 5 20.8 6.8 to 48.6
Rectal CT/GC 83 (32.4) 72.9 12 16.5 8.5 to 28.8
Rectal CT 56 (21.9) 49.8 8 16.1 6.9 to 31.6
Rectal GC 62 (24.2) 54.0 8 14.8 6.4 to 29.2
Excluding participants reporting rectal infection or syphilis 
Pharyngeal infection 25 (16.1) 23.5 0 0 0 to 15.7*
Urethral infection 33 (21.3) 30.6 1 3.3 0.08 to 18.2
*One sided, 97.5% CI.
GC, gonorrhoea CT, chlamydia; PY, person-years.
condom, receptive/insertive sex without a condom and partner 
known to be HIV positive). Follow-up visits, including a full STI 
screen, were scheduled every 3 months.
This analysis is based on participants who were randomised to 
the DEF arm during the period when they did not have access to 
PrEP. An incident HIV infection was defined as a reactive HIV 
antigen-antibody test result, confirmed by the detection of HIV 
RNA, in participants who were HIV negative at enrolment. Orig-
inally, PrEP was planned to be offered at the 12-month scheduled 
visit. However, in October 2014, based on an interim analysis, 
the Independent Data Monitoring Committee recommended 
that all participants should be offered PrEP. Loss to follow-up 
in the trial was low, with HIV status known in 89% of partici-
pants at the end of the deferred phase.2 We additionally sought 
to identify participants who may have been diagnosed with HIV 
in a non-study clinic by linking (based on pseudoanonymised 
identifiers) to the Public Health England (PHE) national data-
base of new HIV diagnoses.12
HIV incidence was compared between different subgroups 
according to baseline data. For participants who acquired HIV, 
date of infection was taken to be the date of the first reactive test. 
Follow-up was censored at the first visit either when a partici-
pant was actually offered PrEP (if they remained in follow-up) or 
when a participant would have been offered PrEP within the trial 
(if they experienced early loss to follow-up). This differs from 
the censoring rules in the main analysis, which were based on 
the timing of HIV tests in study clinics and did not consider PHE 
linkage data. In addition, two participants enrolled twice in the 
trial (first to DEF and then to IMM). In the main analysis, their 
entire follow-up was assigned according to their original rando-
misation allocation (intention to treat); in the present analysis, 
their follow-up is censored at the date of their second rando-
misation (when they were offered PrEP).2 Online supplemen-
tary appendix table 1 summarises the censoring rules described 
above.
Due to the small number of events, we used exact Poisson 
methods (ci command for incidence rates [IR] and expoisson for 
rate ratios [RR] with the midp option). For categorical varia-
bles, the most frequent category was used as the reference group. 
To examine whether incidence changed over the period of 
follow-up, a Weibull model was compared against an exponen-
tial model. Statistical analyses were conducted in Stata V.14.0.
resulTs
A total of 268 participants from the DEF arm were included 
in the analysis after excluding one individual due to a reactive 
HIV antigen-antibody test at enrolment, despite a non-reactive 
point-of-care test. Baseline questionnaires were not completed 
by two individuals and responses were occasionally missing for 
some questions for others (maximum 6.3% missing, table 1, 
footnote). At enrolment, median age was 35 years (IQR: 28–41), 
40.2% were born outside the UK, 69.8% were recruited through 
a London clinic and 55.1% were single (table 1). In the previous 
12 months, 39.5% reported they had been diagnosed with rectal 
chlamydia (CT), rectal gonorrhoea (GC) or syphilis (referred 
to subsequently as a key STI), and 36.7% had received at least 
one PEP prescription. There was wide variability in the reported 
number of anal sex partners in the 90 days prior to enrolment. 
9.2% reported a single partner while 27.5% reported 20 or more 
with a median of 10 (IQR: 4–20). A high proportion reported 
receptive anal intercourse without a condom (ncRAI); 87.5% at 
least once and 11.7% reported 10 or more such partners.
Overall, 21 participants acquired HIV infection over 239.3 PY 
follow-up, yielding an IR of 8.8 per 100 PY (95% CI 5.4 to 13.4 
per 100 PY). Matching with the national HIV new diagnoses 
database yielded an additional 19.4 years of follow-up (from 
31 participants), and one further HIV infection in addition to 
the 20 infections originally reported.2 During the relatively 
short period of follow-up, there was a non-significant (p=0.13) 
increase in HIV incidence (Weibull shape parameter=1.4).
Reporting a diagnosis of a key STI in the previous 12 months 
was a highly significant predictor for HIV acquisition. The IR 
in this subgroup was 17.2 per 100 PY (15/87.0, 95% CI 9.7 to 
28.5), 4.8-fold higher (95% CI 1.8 to 14.9) than the rate for 
men who did not report such a diagnosis. Incidence did not vary 
substantially according to the specific key STI that was reported 
(table 2). Table 2 also shows that HIV incidence was relatively 
low among participants reporting a pharyngeal or urethral STI 
(without a rectal STI).
The other strong predictive factor was the number of self-re-
ported anal sex partners in the previous 90 days, whether this 
was expressed overall, just for receptive sex or further limited 
to condomless sex (online supplementary appendix table 2). 
These variables are highly correlated and therefore difficult to 
distinguish, although the clearest gradient in risk was seen for 
the number of ncRAI partners. A threshold effect was evident, 
with HIV risk sharply elevated for men reporting two or more 
partners; HIV incidence in this subgroup was 13.6 per 100 PY 
(17/125.3, 95% CI 7.9 to 21.7), with an RR of 4.6 (95% CI 
1.5 to 19.8). Thirty-one participants (12.2%) reported that the 
only condomless sex they had was insertive, none of whom 
acquired HIV during follow-up (95% CI 0 to 12.3 per 100 PY); 
16 (51.6%) of these participants were circumcised.
The diagnosis of a key STI in the year prior to enrolment was 
closely related to the number of ncRAI partners in the previous 
3 months. For those with 0, 1, 2–4, 5–9 and 10+partners, 
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Key messages
 ► An important unresolved question in pre-exposure 
prophylaxis (PrEP) programmes is patient eligibility.
 ► As the amount of PrEP is generally limited, it is important 
that it is offered to those at the highest risk of acquiring HIV.
 ► Highest HIV risk was among men who have sex with men 
(MSM) reporting a recent rectal STI or syphilis diagnosis, or 
reporting condomless receptive anal intercourse with two or 
more partners.
 ► HIV-negative MSM with either of these characteristics should 
be offered PrEP as a matter of urgency.
22.6%, 30.7%, 40.0%, 54.5% and 66.7% reported an STI in 
the previous year, respectively (p value for trend <0.001). In a 
bivariate model that included both ncRAI and key STI, the rela-
tive risk estimates for two or more ncRAI partners were attenu-
ated (RR 4.6 to 2.9) but the estimate for the diagnosis of a key 
STI was largely unchanged (RR 4.8 to 4.7). All but one (20/21, 
95.2%) of the HIV infections occurred among the 177 partici-
pants who reported either a key STI or ncRAI with two or more 
partners; the PY observed in the group reporting either of these 
characteristics comprised 63.4% (151.6/239.3) of the overall 
follow-up. The IR of the participants lacking both of these risk 
factors was 1.1 per 100 PY (1/87.6, 95% CI 0.03 to 6.4 per 100 
PY).
Non-significant trends in the expected direction were seen for 
other variables, including PEP use, use of chemsex-associated 
drugs, the number of HIV tests age (younger men at higher risk) 
(table 1). Participants in full-time employment were at higher risk 
of HIV compared to those not in full-time employment. There 
was no effect of location of clinic (London vs non-London) or 
whether the participant was born in the UK. Participants in a 
relationship but who were not cohabiting were at a lower risk 
of HIV infection than either single men or men in a cohabiting 
relationship.
dIsCussIOn
The most powerful individual predictor of HIV infection in 
PROUD was the diagnosis of syphilis or a bacterial rectal infec-
tion (CT/GC) in the previous year; HIV incidence was 17.2 
per 100 PY in this subpopulation. A recent analysis of MSM 
who were repeat attenders at genitourinary medicine (GUM) 
clinics in England identified similar factors but the strength 
of the association was weaker and the proportion of infec-
tions associated with this risk factor was much smaller.13 This 
is likely explained by the lower HIV incidence and smaller 
proportion of attenders with a history of an STI in the national 
study. A secondary analysis of the iPrEx trial examined predic-
tors of HIV infection in the placebo arm.14 The only STI vari-
able reported in this trial was whether an infection had been 
reported in the previous 6 months, irrespective of the type or 
site of infection. This lack of specificity may explain the small 
difference in HIV incidence between participants with (4.9 per 
100 PY) and without (3.6 per 100 PY) an STI report. The 
strong effect in PROUD may be partly due to the regularity of 
STI screening in sexual health clinics in the UK, with partici-
pants receiving a median of three screens in the year prior to 
enrolment.11 Pharyngeal and urethral STIs were not associated 
with an increased HIV risk, suggesting that the selection for 
variables to include in risk algorithms should focus on rectal 
infections and early syphilis.
The other important predictive variable was the number 
of sexual partners in the previous 3 months, particularly 
the number of ncRAI partners. Participants with fewer than 
two ncRAI partners were at a comparatively lower risk of 
HIV infection (2.9 per 100 PY), falling just below the WHO 
threshold of ‘substantial’ risk. The risk fell further below this 
threshold when combined with the absence of a key STI diag-
nosis, suggesting that this subgroup should be a lower priority 
to receive PrEP (ie, one or fewer ncRAI partners in previous 
3 months and no key STI diagnosed in previous 12 months). 
In the extreme case where PrEP confers 100% protection, 
95% of incident HIV infections would have been prevented 
by providing PrEP only to individuals reporting either a key 
STI or ncRAI with two or more partners (63% of the PY of 
follow-up). While the very high HIV incidence in PROUD 
raises the question of generalisability to other lower risk 
settings, we believe this concern applies more to our quantita-
tive estimates than to the findings in general, which should be 
broadly applicable. Another clinically relevant finding was the 
low risk for men who engage exclusively in condomless inser-
tive anal intercourse, mirroring findings in the iPrEx study.14 
However, individual clinical decisions clearly should take into 
account current risk behaviours as well as historical and antic-
ipated ones. The definition of ‘historical’ is also not standard-
ised across guidelines, some referring to the previous 6 months 
and some not specifying a time frame at all.8 9
HIV incidence among PROUD participants without access 
to PrEP was fourfold higher than that of the MSM population 
attending GUM clinics in the UK.2 13 This is likely to repre-
sent an enrichment phenomenon where self-awareness of a 
high risk of acquiring HIV infection motivates individuals to 
seek PrEP.15 If genuine, this phenomenon is favourable for the 
cost-effectiveness of PrEP, which is highly dependent on HIV 
incidence in the group to whom it is offered.16 17 Analyses of 
risk factors for the acquisition of HIV infection have been 
conducted in cohort studies of MSM in several countries,13 18 19 
often with a motivation to inform eligibility criteria for PrEP 
or to identify individuals at particularly high risk who could 
potentially be targeted.14 18 A limitation of these studies was 
an inability to identify those participants who would have 
been interested in taking PrEP had it been available. The key 
strength of this secondary analysis of PROUD is the restric-
tion to MSM who were either actively seeking PrEP or had 
accepted a clinical recommendation from their clinician.
The main limitation of our analysis is the low number of 
incident HIV infections, but this was unavoidable due to the 
size of the trial. The consequences are twofold: imprecise esti-
mates of HIV incidence and an inability to undertake multivar-
iate analyses to develop a risk algorithm. Although PrEP was 
not available through the National Health Service during the 
study period, some participants in the deferred arm may have 
accessed it through other means. PEP use was also common 
with 174 courses prescribed to 85 participants during the 
study period,2 which could have further reduced the estimated 
incidence. Finally, our results are sensitive to the specific recall 
periods that were used in the questionnaires.
In conclusion, the high HIV incidence in PROUD suggests 
that participants appropriately judged their risk of acquiring 
HIV and the benefits of PrEP. Eligibility criteria for a PrEP 
programme following PROUD can therefore be broad for 
MSM, as in the current guidelines. However, the risk of 
acquiring HIV is declining in some settings due to increased 
PrEP coverage, an increase in HIV testing and rapid treatment 
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after an HIV diagnosis.6 20 This complicates this judgement and 
may change the predictive value of individual risk factors. In 
particular, we note a possible further reduction in the already 
low risk for those reporting only one partner with whom they 
had not used a condom for receptive anal sex and it will be 
important to continue to review the need for PrEP in this 
group. However, a recent history of syphilis, rectal CT/GC 
or two or more ncRAI partners indicates a high imminent risk 
of HIV infection, and HIV-negative MSM with any of these 
characteristics should be offered PrEP as a matter of urgency.
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